膀胱癌中CDH13基因启动子甲基化的临床意义

The clinical significance of the promoter methylation of CDH13 gene in bladder cancer

目的探讨膀胱癌中CDH13基因启动子甲基化的临床意义。方法应用甲基化特异性PCR检测在23例正常膀胱黏膜和71例原发性膀胱移行细胞癌组织中CDH13基因启动子甲基化状态，并结合膀胱癌临床病理资料进行统计学分析。结果在23例正常膀胱黏膜组织中CDH13基因启动子均未出现甲基化，在71例膀胱癌组织中CDH13基因启动子甲基化率为60．6％，两组相比差异有统计学意义（P〈0．01）；在膀胱癌组织中CDH13基因启动子甲基化与患者年龄、性别、肿瘤数目和肿瘤形态无关（P〉0．05），但是与肿瘤的生长、分化不良以及侵袭密切相关（P〈0．05）。结论CDH13基因启动子甲基化与膀胱癌的发生发展密切相关，有可能成为膀胱癌早期诊断、监测和预后判断的分子标志物。

Objectives The aim of this study was to investigate the clinical significance of the promoter methylation of CDH13 gene in bladder cancer. Methods The promoter methylation of CDH13 gene in 23 normal bladder mucosa and 71 bladder transitional cell carcinoma tissues was detected using methylation specific polymerase chain reaction （ MSP）, and correlated with clinicopathological data of bladder cancer patients. Results The methylation rate CDH13 gene in 71 bladder transitional cell carcinoma tissues was 60.6%, however no methylation was found in 23 normal bladder mucosa tissues, and the difference was statistically significant （ P 〈 0.01 ）. The promoter methylation of CDH13 gene in bladder transitional cell carcinoma tissues was unrelated with patient＇s age, gender, tumor number or tumor shape （ P 〉 0.05 ）, but correlated with tumor growth, poor differentiation and tumor invasion（ P 〈 0.05）. Conclusions The promoter methylation is closely correlated with the occurrence and development of bladder cancer, and which may be used as a potential biomarker for the early diagnosis, monitoring and prognosis of bladder cancer.